Boots courts +£11bn in UK high-street care race
This article was originally published in Clinica
Executive Summary
The final outcome of the race between US consortium Kohlberg Kravis Roberts (KKR) and Terra Firma to buy UK pharmacy, healthcare services and beauty group Alliance Boots could have implications for the wider UK independent healthcare sector. Today, the KKR-led company AB Acquisitions raised its offer for Boots, valuing it at £11.1bn ($22.2bn), trumping an "indicative proposal" from UK-based private equity group Terra Firma, worth £10.8bn.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.